Shares of Zoetis (ZTS) have risen 15.4% in the past three months compared with the industry’s 9.3% growth. The stock has also outperformed the sector as well as the S&P 500 as seen in the chart below. The stock is also trading above both its 50 and 200-day moving averages from early August.ZTS Stock Outperforms Industry, Sector & S&P 500    Image Source: Zacks Investment ResearchZoetis is a major player in the animal health market. The company operates in eight major product categories: vaccines, anti-infec ...

Zoetis (ZTS) closed at $191.09 in the latest trading session, marking a +0.2% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.54%. Elsewhere, the Dow saw an upswing of 0.72%, while the tech-heavy Nasdaq appreciated by 0.65%. Shares of the animal health company witnessed a gain of 3.6% over the previous month, trailing the performance of the Medical sector with its gain of 4.37% and the S&P 500's gain of 4.86%. The investment community will be closely monitoring the pe ...

It has been about a month since the last earnings report for Zoetis (ZTS) . Shares have added about 1.4% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Zoetis due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Zoetis Q2 Earnings & Revenues Beat, ’24 Outlook RaisedZo ...

Zoetis Inc (NYSE:ZTS) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 1:05 PM ET Company Participants Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Erin Wright Thanks, and good afternoon, everyone. Welcome to the Morgan Stanley Healthcare Conference. I'm Erin Wright, Lead Healthcare Services Analyst at Morgan Stanley. We're happy to have with us today, Zoetis' CEO, Kristin Peck with us; as ...

Olena Miroshnichenko/iStock via Getty Images Last month, I published a deep dive into Zoetis' (NYSE:ZTS) business. As with any pharma company, its pipeline is critical to its future growth. Librela is expected to be one of their most successful drugs, but I believe management is heavily sandbagging its $1B peak sales target for the medication: Management's expectation (2023 Investor Day) What Is Librela Librela is a first-of-its-kind medication targeting the treatment of Osteoarthritis (OA) in dogs, a ...

Group 1 - Zoetis (ZTS) has surpassed resistance at the 20-day moving average, indicating a short-term bullish trend [1] - The stock has rallied 6.3% over the past four weeks, suggesting potential for further gains [3] - Positive earnings estimate revisions have occurred, with one revision higher for the current fiscal year and none lower, leading to an upward movement in the consensus estimate [3] Group 2 - The 20-day simple moving average is a favored tool among traders, providing insights into short-term price trends and trend reversals [1] - The combination of technical indicators and earnings estimate revisions positions ZTS favorably for potential upward movement [3]

From a technical perspective, Zoetis (ZTS) is looking like an interesting pick, as it just reached a key level of support. ZTS recently overtook the 200-day moving average, and this suggests a long-term bullish trend.The 200-day simple moving average is widely-used by traders and analysts, and helps establish market trends for stocks, commodities, indexes, and other financial instruments over the long term. The indicator moves higher or lower together with longer-term price moves, serving as a support or re ...

Monty RakusenI published my ‘Hold’ thesis on Zoetis (NYSE:ZTS) in July 2023, highlighting the high quality of Zoetis’ companion business while expressing concerns about its elevated stock price. Since my last publication, the stock price increased by 8.6%, underperforming compared to the S&P 500 (SP500) index return of 15.8%. The company released its Q2 earnings on August 6th before the market opened and raised its full-year guidance. I believe the companion business will experience double-digit growth ...

Zoetis (ZTS) reported $2.36 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 8.3%. EPS of $1.56 for the same period compares to $1.41 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.3 billion, representing a surprise of +2.53%. The company delivered an EPS surprise of +4.70%, with the consensus EPS estimate being $1.49.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expect ...

Key TakeawaysZoetis raised its full-year revenue guidance by $50 million at the midpoint.The company topped second-quarter expectations on revenue but fell just short on earnings per share (EPS).Shares surged 6% in intraday trading Tuesday. Zoetis (ZTS) stock surged in intraday trading Tuesday after the company beat second-quarter revenue expectations and raised its full-year guidance. The veterinary drugmaker now expects full-year revenue of $9.1 billion to $9.25 billion, up from its prior forecast of $9.0 ...